Martin Gilbert Pomper

USPTO Granted Patents = 65 (Patent Applications = 67)

CIPO Patents = 11 (Patent Applications = 9)

EPO Patents = 22 (Patent Applications = 42)

Average Co-Inventor Count = 4.1

ph-index = 10

Forward Citations = 432(Granted Patents)

Forward Citations (Not Self Cited) = 384(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

63 out of 3,687

Johns Hopkins University

Virginia Commonwealth University

patents

4. 1 out of 2,119

Northwestern University

patents

5. 1 out of 3,100

Chinese Academy of Sciences

patents

6. 1 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

7. 1 out of 1

Institute of Biotechnology Cas, V.v.i.

patent

8. 1 out of 505

Oregon Health & Science University

patents

9. 1 out of 1,381

University of Colorado

patents

10. 2 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

Areas of Expertise:

Prostate-Specific Membrane Antigen

Cancer Radiotherapy

Molecular Imaging

Fluorescent Agents

Theranostic Gene Therapy

Monoclonal Antibodies

Raman Spectroscopy

Nanoparticle Delivery

Immunotherapy

Nuclear Imaging

Photosensitizers

Chemical Exchange Saturation Transfer

65 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12233137 - PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy (2025-02-25),

2. 12165036 - Methods and related aspects for pathology prognosis (2024-12-10),

3. 12115233 - Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α) (2024-10-15),

4. 12104214 - PSMA-based molecular-genetic reporter system (2024-10-01),

5. 12070513 - PSMA-binding agents and uses thereof (2024-08-27),

6. 12065413 - PSMA targeted fluorescent agents for image guided surgery (2024-08-20),

7. 11938201 - Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (FAP-alpha) (2024-03-26),

8. 11911488 - Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy (2024-02-27),

9. 11886975 - Methods and related aspects for pathology prognosis (2024-01-30),

10. 11871895 - Raman spectroscopy reporters and methods for molecular imaging of tissue in vivo (2024-01-16),

11. 11851407 - Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [F]DCFPYL (2023-12-26),

12. 11814365 - PSMA targeted fluorescent agents for image guided surgery (2023-11-14),

13. 11813340 - PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy (2023-11-14),

14. 11773182 - Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) (2023-10-03),

15. 11739063 - DREADD actuators (2023-08-29),

Title: Innovator Spotlight: Martin Gilbert Pomper Revolutionizing Imaging and Cancer Therapy

Introduction:

Martin Gilbert Pomper, based in Baltimore, MD, is a prolific inventor with an impressive portfolio of 59 patents. His groundbreaking work revolves around imaging and radiotherapeutics agents that target specific proteins, paving the way for more accurate diagnostics and effective treatments for various diseases and disorders.

Latest Patents:

Recently, Pomper introduced two cutting-edge patents. The first focuses on Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (FAP-alpha), offering a novel approach to imaging and treating FAP-alpha related conditions. The second patent highlights innovative scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy, showcasing his commitment to advancing cancer diagnostics and treatment.

Career Highlights:

With a strong background in medical research, Martin Gilbert Pomper has made significant contributions during his tenure at The Johns Hopkins University and other renowned institutions. His expertise in molecular imaging and cancer therapeutics has led to the development of revolutionary technologies that are shaping the future of healthcare.

Collaborations:

Pomper's collaborative efforts with esteemed coworkers like Ronnie Charles Mease and Sangeeta Ray have further amplified the impact of his inventions. Together, they have forged new pathways in the field of medical imaging and cancer research, garnering recognition for their innovative approaches and groundbreaking discoveries.

Conclusion:

Inventor Martin Gilbert Pomper's dedication to pushing the boundaries of medical innovation is evident in his extensive patent portfolio and groundbreaking inventions. His relentless pursuit of excellence and collaborations with top experts in the field underscore his commitment to revolutionizing imaging techniques and cancer therapy, ultimately improving patient outcomes and advancing the realm of medical science.

This text is generated by artificial intelligence and may not be accurate.